As heart transplant recipients may be at increased risk for infection with COVID-19, investigators sought to identify characteristics, treatment, and outcomes of this patient population.
A more accurate prediction for assessing the eligibility of candidates for liver transplantation who received neoadjuvant therapies was shown when mRECIST radiologic response was included within the Metroticket 2.0 framework.
Patients undergoing allogeneic hematopoietic cell transplantation who have greater intestinal microbiota diversity may have a lower risk for mortality.
Donor cytomegalovirus seropositivity at transplantation was associated with an increased risk for thrombotic events post-transplantation.
Among recipients of allogeneic hematopoietic cell transplantation (allo-HCT), gram-negative intestinal colonization is highly predictive of bloodstream infections.
Patients who received heart transplants from hepatitis C virus-positive vs -negative donors were found to have comparable survival at 1 year and patients who developed transplant-related hepatitis C responded well to treatment.
Untreated chronic oral infection is not associated with post-hematopoietic stem cell transplant outcomes.
Adult heart transplants from hepatitis C virus-positive donors appear safe, with no increased risk for adverse effects on one-year survival.
Many pediatric liver transplant recipients are undervaccinated.
Early-onset pneumonia with multidrug-resistant organisms is a major concern for patients who have received a liver transplant, and pre- and intra-operative risk factors influence its development, according to study data presented at The American Association for the Study of Liver Diseases’ The Liver Meeting, held November 8 to 12, 2019 in Boston, Massachusetts. In an…
